RADX Stock Analysis: Buy, Sell, or Hold?
RADX - Radiopharm Theranostics Limited American Depositary Shares
$2.80
0.01 (0.36%)
▲
5d:
-11.11%
30d:
-33.96%
90d:
-39.0%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Feb 26, 2026
0d
Get Alerted When RADX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RADX is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RADX is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RADX is currently trading at $2.80, which is considered oversold relative to its 30-day fair value range of $3.17 to $4.41.
Technical Outlook: Technically, RADX is in a downtrend. Immediate support is located at $2.62, while resistance sits at $3.88.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.14 (+512.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RADX is in a downtrend. Immediate support is located at $2.62, while resistance sits at $3.88.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.14 (+512.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.17 -
$4.41
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 512.1% below Wall St target ($17.14)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.17 -
$4.41
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.62
Resistance Level
$3.88
Current Trend
Downtrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.87
Wall Street Target
$17.14
(+512.1%)
Revenue Growth (YoY)
154.5%
Profit Margin
-286.2%
Share & Embed Analysis
Last updated: August 09, 2026 1:10 AM ET
Data refreshes hourly during market hours. Next update: 2:10 AM
Data refreshes hourly during market hours. Next update: 2:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RADX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 47 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 35 SELL |
